Chimeric west nile/dengue viruses
The disclosure provides chimeric West Nile/Dengue viruses comprising non-coding regions, non-structural proteins, and a C protein from a West Nile virus and prM and E proteins from a Dengue virus. Also disclosed are methods of using the chimeric viruses in diagnosis of Dengue viral infection, assessment of candidate Dengue virus vaccine efficacy, and production of Dengue prM and E proteins.
1. A nucleic acid chimera comprising:
a first nucleic acid molecule comprising a 5′ non-coding region, a nucleic acid encoding a C protein and non-structural proteins, and a 3′ non-coding region from a West Nile virus genome; and
a second nucleic acid molecule operably linked to the first nucleic acid molecule, encoding at least a portion of a prM protein and E protein from a Dengue virus genome.
2. The chimera of claim 1 , wherein the West Nile virus genome is a NY99 West Nile virus strain genome.
3. The chimera of claim 1 , wherein the Dengue virus genome is a Dengue-1, Dengue-2, Dengue-3, or Dengue-4 genome.
4. The chimera of claim 1 , wherein the Dengue virus genome comprises a 16681 Dengue-2 virus strain genome.
5. The chimera of claim 1 , wherein the second nucleic acid molecule encodes at least one amino acid substitution in the E protein, wherein the substitution increases virus titer, replication rate, plaque size, or stability in cell culture.
6. The chimera of claim 5 , wherein the at least one amino acid substitution in the E protein comprises a substitution at amino acid position 64, 122, 186, 203, or a combination of two or more thereof.
7. The chimera of claim 6 , wherein the at least one amino acid substitution in the E protein is one or more of K122I, S186F, and N203D.
8. The chimera of claim 1 , wherein the second nucleic acid molecule encodes at least one amino acid substitution in the prM protein, wherein the substitution increases virus titer, replication rate, plaque size, or stability in cell culture.
9. The chimera of claim 1 , wherein the first nucleic acid molecule encodes at least one amino acid substitution in one or more of the non-structural proteins or the C protein, wherein the substitution increases virus titer, replication rate, plaque size, or stability in cell culture, or decreases infectivity in mosquitoes.
10. The chimera of claim 9 , wherein the amino acid substitution is a substitution selected from the group consisting of position 49 of non-structural protein 2A (NS2A), position 94 of NS2A, position 241 of non-structural protein 4B (NS4B), and a combination of two or more thereof.
11. The chimera of claim 10 , wherein the amino acid substitution is one or more of NS2A I49T, NS2A F94L, and NS4B T241I.
12. The chimera of claim 1 , wherein the first nucleic acid molecule comprises at least one nucleic acid substitution in the 5′ non-coding region or the 3′non-coding region of the West Nile virus genome, wherein the substitution increases virus titer, replication rate, plaque size, or stability in cell culture, or decreases infectivity in mosquitoes.
13. The chimera of claim 1 , wherein the second nucleic acid molecule encodes at least one amino acid substitution in the E protein, wherein the substituted E-protein exhibits measurably reduced antibody cross-reactivity.
14. The chimera of claim 13 , wherein the at least one amino acid substitution in the E protein comprises a substitution at amino acid position 101, 106, 107, 108, 135, or a combination of two or more thereof.
15. The chimera of claim 1 , having a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, and nucleic acid sequences at least 95% identical to at least one of SEQ ID NOs: 1, 3, 5, or 7.
16. The chimera of claim 1 , having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, and amino acid sequences at least 95% identical to at least one of SEQ ID NOs: 2, 4, 6, or 8.
17. A method of detecting a Dengue virus antibody in a sample from a subject, comprising:
contacting the sample with a virus encoded by the chimera of claim 1 to form a virus-sample mixture;
inoculating a susceptible monolayer cell culture with the virus-sample mixture;
incubating the cell culture under conditions sufficient to allow virus replication;
counting plaques, counting immunostained foci, or measuring viral antigen level in the culture; and
comparing the number of plaques, the number of foci, or the viral antigen level to a control culture, wherein a decrease in the number of plaques, number of foci, or viral antigen level as compared to the control culture indicates the Dengue virus antibody is present in the sample.
18. A method of evaluating efficacy of a candidate Dengue virus vaccine, comprising:
immunizing a set of subjects with the candidate Dengue virus vaccine;
waiting sufficient time for an immune response to develop;
challenging the subjects by inoculating the subjects with a virus encoded by the chimera of claim 1 ;
waiting sufficient time for viremia, morbidity and/or mortality to develop; and
comparing viremia, morbidity and/or mortality of the subjects with a set of non-immunized control subjects which has not been immunized with the candidate Dengue virus vaccine, wherein a decrease in viremia, morbidity and/or mortality as compared with the control subjects indicates efficacy of the candidate Dengue virus vaccine.
19. A method of producing virus particles expressing Dengue virus prM, M, and E proteins, comprising:
culturing a virus encoded by the chimera of claim 1 in a cell, wherein virus particles comprising one or more Dengue prM, M, or E proteins are produced;
collecting a supernatant from the cell culture containing the chimera; and
purifying the virus particles from the supernatant.
20. A chimeric flavivirus or virus particle comprising the nucleic acid chimera of claim 1 .
21. A mouse inoculated with the nucleic acid chimera of claim 1 .
22. A mouse inoculated with a chimeric flavivirus or virus particle comprising the nucleic acid chimera of claim 1 .